

To: Minister van VWS [redacted] [redacted]@minvws.nl]
Cc: [redacted] [redacted] [redacted]@astrazeneca.com]
From: [redacted] [redacted]
Sent: Wed 12/9/2020 4:26:23 PM
Subject: AstraZeneca vaccine interim data published in The Lancet
Received: Wed 12/9/2020 4:26:44 PM
[201208 - Phase III AZD1222 Interim Results Lancet.pdf](#)

Dear Minister de Jonge, Dear Minister Van Ark,

I would like to share that our interim data on the AstraZeneca/Oxford vaccine (AZD1222) has now been published in a peer reviewed journal, The Lancet.
This is the first peer reviewed publication of data for a Covid vaccine.

The data is currently under review by regulatory authorities and we will keep you informed.

If you or your team have any questions please do not hesitate to contact us.

Kind regards,

[redacted]
5.1.2e

AstraZeneca

M: [redacted] [redacted]
[redacted]@astrazeneca.com

PA: [redacted] [redacted] T: +31 [redacted]
[redacted]@astrazeneca.com

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com